tiprankstipranks
In this article:
Blurbs

Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX), Oramed Pharmaceuticals (ORMP) and Citius Pharmaceuticals (CTXR)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repare Therapeutics (RPTXResearch Report), Oramed Pharmaceuticals (ORMPResearch Report) and Citius Pharmaceuticals (CTXRResearch Report) with bullish sentiments.

Repare Therapeutics (RPTX)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Repare Therapeutics, with a price target of $54.00. The company’s shares closed last Friday at $15.23, close to its 52-week low of $13.97.

According to TipRanks.com, Burns is ranked 0 out of 5 stars with an average return of -18.3% and a 19.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Black Diamond Therapeutics, and Turning Point Therapeutics.

Currently, the analyst consensus on Repare Therapeutics is a Strong Buy with an average price target of $48.20.

See the top stocks recommended by analysts >>

Oramed Pharmaceuticals (ORMP)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oramed Pharmaceuticals, with a price target of $32.00. The company’s shares closed last Friday at $11.05.

According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -24.8% and a 20.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals.

Oramed Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $34.25.

Citius Pharmaceuticals (CTXR)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Citius Pharmaceuticals today and set a price target of $6.00. The company’s shares closed last Friday at $1.53, close to its 52-week low of $1.07.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 28.0% and a 35.3% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Eledon Pharmaceuticals, and Achieve Life Sciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Citius Pharmaceuticals with a $6.67 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RPTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed